152 related articles for article (PubMed ID: 15598660)
1. CD80 binding polyproline helical peptide inhibits T cell activation.
Srinivasan M; Lu D; Eri R; Brand DD; Haque A; Blum JS
J Biol Chem; 2005 Mar; 280(11):10149-55. PubMed ID: 15598660
[TBL] [Abstract][Full Text] [Related]
2. Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent.
Srinivasan M; Eri R; Zunt SL; Summerlin DJ; Brand DD; Blum JS
Arthritis Rheum; 2007 Feb; 56(2):498-508. PubMed ID: 17265485
[TBL] [Abstract][Full Text] [Related]
3. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
[TBL] [Abstract][Full Text] [Related]
4. What's the difference between CD80 and CD86?
Sansom DM; Manzotti CN; Zheng Y
Trends Immunol; 2003 Jun; 24(6):314-9. PubMed ID: 12810107
[TBL] [Abstract][Full Text] [Related]
5. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A; Reddy M; Ryan P; Lyn SD; Eichman C; Couez D; Hurle MR; Sekaly RP; Olive D; Sweet R
Mol Immunol; 1996 Feb; 33(3):321-34. PubMed ID: 8649453
[TBL] [Abstract][Full Text] [Related]
6. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro.
Srinivasan M; Wardrop RM; Gienapp IE; Stuckman SS; Whitacre CC; Kaumaya PT
J Immunol; 2001 Jul; 167(1):578-85. PubMed ID: 11418697
[TBL] [Abstract][Full Text] [Related]
7. Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling.
Sørensen P; Kussmann M; Rosén A; Bennett KL; Thrige Dda G; Uvebrant K; Walse B; Roepstorff P; Björk P
J Immunol; 2004 Jun; 172(11):6803-9. PubMed ID: 15153498
[TBL] [Abstract][Full Text] [Related]
8. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
9. Interactions of CD80 and CD86 with CD28 and CTLA4.
Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
[TBL] [Abstract][Full Text] [Related]
10. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
[TBL] [Abstract][Full Text] [Related]
11. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Lazetic S; Leong SR; Chang JC; Ong R; Dawes G; Punnonen J
J Biol Chem; 2002 Oct; 277(41):38660-8. PubMed ID: 12167647
[TBL] [Abstract][Full Text] [Related]
12. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
[TBL] [Abstract][Full Text] [Related]
13. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
[TBL] [Abstract][Full Text] [Related]
14. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.
Darlington PJ; Kirchhof MG; Criado G; Sondhi J; Madrenas J
J Immunol; 2005 Jul; 175(2):996-1004. PubMed ID: 16002699
[TBL] [Abstract][Full Text] [Related]
15. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28.
Srinivasan M; Gienapp IE; Stuckman SS; Rogers CJ; Jewell SD; Kaumaya PT; Whitacre CC
J Immunol; 2002 Aug; 169(4):2180-8. PubMed ID: 12165548
[TBL] [Abstract][Full Text] [Related]
16. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
17. A theoretical framework for quantitative analysis of the molecular basis of costimulation.
Jansson A; Barnes E; Klenerman P; Harlén M; Sørensen P; Davis SJ; Nilsson P
J Immunol; 2005 Aug; 175(3):1575-85. PubMed ID: 16034096
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.
Metzler WJ; Bajorath J; Fenderson W; Shaw SY; Constantine KL; Naemura J; Leytze G; Peach RJ; Lavoie TB; Mueller L; Linsley PS
Nat Struct Biol; 1997 Jul; 4(7):527-31. PubMed ID: 9228944
[TBL] [Abstract][Full Text] [Related]
19. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
[TBL] [Abstract][Full Text] [Related]
20. Effect of CD80 and CD86 on T cell cytokine production.
Petro TM; Chen SS; Panther RB
Immunol Invest; 1995 Nov; 24(6):965-76. PubMed ID: 8575841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
